anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Demyelination is the loss of myelin in CNS, resulting in damaged myelin sheath. Oxidative stress and neuroinflammation play a key role in inducing demyelinating diseases like MS; hence, controlling oxidative stress and neuroinflammation is important. Cuprizone (CPZ), a copper chelator, generates oxidative stress and neuroinflammation, thereby inducing demyelination. Therefore, the CPZ-induced demyelinating mouse model (CPZ model) is widely used in research. The present study was intended to unravel a mechanism of inhibition of demyelination by arsenic in a CPZ model, which is otherwise known for its toxicity. We investigated an alternative mechanism of inhibition of demyelination by arsenic through the reversal of SOD1 activity employing in silico analysis, analytical chemistry techniques, and in vitro and in vivo experiments. In vivo experiments showed protection of body weight, survivability, and myelination of the corpus callosum in CPZ and arsenic-co-exposed animals, where neuroinflammation was apparently not involved. In vitro experiments revealed that arsenic-mediated reversal of impaired SOD1 activity leads to reduced cellular ROS levels and better viability of primary oligodendrocytes. Reversal of SOD1 activity was also observed in the corpus callosum tissue isolated from experimental animals. In silico and analytical chemistry studies revealed that similar to copper, arsenic can potentially bind to CPZ and thereby make the copper freely available for SOD1 activity. Suitable neurobehavior tests further validated the protective effect of arsenic. Taken together, the present study revealed that arsenic protects oligodendrocytes and demyelination of corpus callosum by reversing CPZ-induced impaired SOD1 activity.
JYNARQUE can cause serious and potentially fatal liver injury. Acute liver failure requiring liver transplantation has been reported in the post-marketing ADPKD experience. Discontinuation in response to laboratory abnormalities or signs or symptoms of liver injury (such as fatigue, anorexia, nausea, right upper abdominal discomfort, vomiting, fever, rash, pruritus, icterus, dark urine or jaundice) can reduce the risk of severe hepatotoxicity.

In a 3-year placebo-controlled trial and its open-label extension (in which patients' liver tests were monitored every 4 months), evidence of serious hepatocellular injury (elevations of hepatic transaminases of at least 3 times ULN combined with elevated bilirubin at least 2 times the ULN) occurred in 0.2% (3/1487) of tolvaptan treated patients compared to none of the placebo treated patients.

To reduce the risk of significant or irreversible liver injury, assess ALT, AST and bilirubin prior to initiation of JYNARQUE, at 2 weeks and 4 weeks after initiation, then monthly for 18 months and every 3 months thereafter.

At the onset of signs or symptoms consistent with hepatic injury or if ALT, AST, or bilirubin increase to >2 times ULN, immediately discontinue JYNARQUE, obtain repeat tests as soon as possible (within 48 to 72 hours), and continue testing as appropriate. If laboratory abnormalities stabilize or resolve, JYNARQUE may be reinitiated with increased frequency of monitoring as long as ALT and AST remain below 3 times ULN.

Do not restart JYNARQUE in patients who experience signs or symptoms consistent with hepatic injury or whose ALT or AST ever exceeds 3 times ULN during treatment with tolvaptan, unless there is another explanation for liver injury and the injury has resolved.

In patients with a stable, low baseline AST or ALT, an increase above 2 times baseline, even if less than 2 times upper limit of normal, may indicate early liver injury. Such elevations may warrant treatment suspension and prompt (48 to 72 hours) re-evaluation of liver test trends prior to reinitiating therapy with more frequent monitoring.
The purpose of this study is to assess the safety and efficacy of low level red light therapy in myopia control in African, Hispanic, and Caucasian children. This is a prospective, multi-ethnic, parallel-controlled randomized trial that will enroll myopic children aged 8-13 years old as subjects. On top of wearing single vision spectacles, subjects in the intervention group will receive treatment twice a day from Monday to Friday, with each treatment lasting for 3 minutes at a minimal interval of 4 hours. Subjects in the control group will wear single vision spectacles. The study will evaluate axial elongation, cycloplegic spherical equivalent change, changes in other biological parameters (except axial length), and uncorrected and best corrected visual acuity of the two groups of subjects at 1 month, 3 months, 6 months, and 12 months after enrollment. The study plans to conduct an interim analysis at a three-month follow-up. The enrollment target is 90 participants: 30 Hispanic Children (15 control and 15 treatment) , 30 African Children (15 control and 15 treatment), and 30 Caucasian Children (15 control and 15 treatment).
The subject invention pertains to methods and compositions for wound treatment. The methods and compositions provide for promoting and accelerating wound healing; provide for inhibition of microbial infection; provide for a protective scab-like covering on a wound; and/or for arresting the flow of blood or body fluids from an open wound. The methods and compositions can be used to increase granulation and epithelialization in a wound. In one embodiment, a substantially anhydrous compound of a salt ferrate and a cation exchange material is provided. Compositions of the invention can also include silver compounds. In use, compositions of the invention are preferably applied as a dry dressing to an exuding chronic wound site. If the chronic wound site is dry, the wound site may be wetted with a suitable liquid or aqueous media prior to applying the dressing in dry form.
PURPOSE:To obtain a pasty base, containing a polydiorganosiloxane and water- soluble polymer and capable of staying on the surfaces of wet mucous membranes and providing protective effects on ulcerated surfaces, etc. CONSTITUTION:A pasty base containing a polydiorganosiloxane and a water-soluble polymer as ingredients. A polydiorganosiloxane which is liquid or gummy at ambient temperature, e.g. silicone oil having >=10cSt viscosity or raw rubber having >=1000000cSt viscosity both at 25 deg.C. The water-soluble polymer preferably has higher consistency and, e.g. polyacrylic acid, a water-soluble salt thereof or polyacrylamide, etc., is used.
Providers will receive a monthly in-basket messages linking to a list of patients who have been seen in the past 2 months or will be seen in the upcoming month with HFrEF who are not on MRA (and who do not have contraindication to MRA). This list will display each patient's current hFrEF therapies, EF, blood pressure, potassium, glomerular filtration rate, date of last visit, and date of next visit. From the list, providers can access the patient's chart, order medications, and document communication with the patient.
This is a two-arm, randomized-controlled pilot study with 2 year duration. The "intervention" refers to surveillance based on the EAU guidelines and the "control" refers to surveillance based on the AUA guidelines.

Research methods: Participants who presents with non-muscle invasive bladder cancer and meets the inclusion/exclusion criteria will be given an option to participate in the study. Participants will be enrolled at the Urology Clinics at the University of Texas Health Science Center San Antonio (UTHSCSA) Medical Arts and Research Center (MARC) and South Texas Veterans Health Care System (STVHCS). Non-local site include the University of Texas Southwestern Medical Center (UTSW). The research procedures consist of urine collection, cystoscopy, and patient satisfaction and cost questionnaires. The evaluation will be done by the tumor recurrence and progression of the disease. At various time points throughout the study, urine may be obtained from the patient and banked in the Genitourinary (GU) Tissue Bank. Subjects asked to provide a urine sample(s) will be asked to sign a separate informed consent. The urine is de-identified in the lab per the Health Insurance Portability and Accountability Act (HIPAA) protocol GU Tissue Bank Institutional Review Board (IRB) # 20050234H). Patients will undergo cystoscopy in clinic (standard of care). In the intervention arm, patient surveillance cystoscopy will be performed at 3, 12 months and again at 24 months following the diagnosis of bladder cancer. Patients randomized to the control arm, will undergo surveillance cystoscopy every 3 months for 2 years following the diagnosis of bladder cancer. Because use of cytology is variable among the participating urologist, the utilization of cytology will be at the treating urologist's discretion as per usual standard care. Study duration will be 2 years from most recent biopsy. Patients will be placed on the surveillance schedule based on the length of time from their last tumor.
PURPOSE:To obtain a double-layered makeup cosmetic giving durable makeup and having smooth spreadability and refreshing feeling by compounding powder, a silicon oil component, a silicone resin and an organopolysiloxane modified with polyoxyalkylene. CONSTITUTION:The objective double-layered makeup cosmetic giving durable makeup and having smooth spreadability and unique refreshing feeling can be produced by compounding powder (e.g. 12 nylon powder), a silicone oil component (e.g. decamethylcyclopentasiloxane), a silicone resin (e.g. trimethylsiloxysilicate) and an organopolysiloxane modified with polyoxyalkylene. The cosmetic is separated into two layers consisting of an oil layer and a powder layer when left to stand over a long period and, accordingly, it can uniformly be dispersed by shaking in use. The cosmetic has excellent redispersibility of the powder.
Acute pancreatitis has been reported in the postmarketing setting and in randomized clinical trials. In glycemic control trials in patients with type 2 diabetes mellitus, acute pancreatitis was reported in 6 (0.2%) patients treated with NESINA 25 mg and 2 (<0.1%) patients treated with active comparators or placebo. In the EXAMINE trial (a cardiovascular outcomes trial of patients with type 2 diabetes mellitus and high cardiovascular (CV) risk), acute pancreatitis was reported in 10 (0.4%) of patients treated with NESINA and in 7 (0.3%) of patients treated with placebo.

It is unknown whether patients with a history of pancreatitis are at increased risk for pancreatitis while using NESINA.

After initiation of NESINA, patients should be observed for signs and symptoms of pancreatitis. If pancreatitis is suspected, NESINA should promptly be discontinued and appropriate management should be initiated.
PROBLEM TO BE SOLVED: To obtain the subject dietary fiber having both improving action on a serum liquid value and inhibitory action on a secondary metabolite of bile acid as a carcinogenic substance, by partially hydrolyzing a mannan of devil's tongue with a cellulase derived from a microorganism to lover the molecular weight of mannan. SOLUTION: Devil's tongue powder is decolored and deodorized with >=80% (V/V) ethanol, dried and made into a 1% aqueous solution, which is reacted with a powdery cellulose derived from a microorganism in an amount of 1/100 that of the devil's tongue at 25-30 deg.C for 30 minutes, partially hydrolyzed and molecular weight-lowered under stirring by a homomixer. The M.W. lowered substance is heated at 95 deg.C for 10 minutes to deactivate the enzyme. The produced insoluble substance is removed by filtration by a diatomaceous earth and the prepared clear solution is concentrated and spray-dried to give the objective dietary fiber of M.W. lowered devil's tongue having >=20,000 average molecular weight range, about 50,000 average molecular weight and 15-30cpm viscosity at 1% solution.
BACKGROUND: In light of the exponential rise in global population, there is a critical requirement to reduce food waste on a global scale. According to studies, agricultural wastes such as oil-seed cakes offer great nutritional value. Acid precipitation (A) and alkaline extraction methods (traditional methods) were used to extract protein from oil-seed cakes; however, both procedures are linked to decreased protein quality and quantity, which prompted the development of a novel strategy known as the biological/microbial/probiotic (B) method. Therefore, the present study aimed to highlight the optimal way of protein extraction from oil-seed cakes and the effect of extraction methods on protein efficacy against obesity. The outcomes were also compared with milk proteins.
RESULTS: In vitro study provided evidence that proteins from both sources (plant and milk) suppressed adipogenesis and stimulated adipolysis in 3T3L-1 cells. For the in vivo study, mice were fed with different protein extracts: soya protein preparation (SPP), ground protein preparation (GPP), whey protein (WP) and casein protein (CP) containing 40% of their calories as fat. Body weight decreased significantly in all the rats except CP-fed rats. Body mass index, atherogenic index, plasma triglyceride and very-low-density lipoprotein cholesterol level decreased significantly in all the groups in comparison to the model group (high-fat-diet group), but the decrease was more pronounced in plant proteins than milk proteins. In hepatocytes, the expression of fasting-induced adipose factor, carnitine palmitoyltransferase I and peroxisome proliferator-activated receptor α genes was increased significantly in SPP-fed groups. Adiponectin gene expression was upregulated significantly in visceral fat tissue in groups fed SPP-B, GPP-A and CP, whereas leptin gene was downregulated significantly in all groups except SPP-A.
CONCLUSION: This study demonstrates that SPP-B showed the most effective anti-obesity property, followed by WP. Additionally, we found that the biological precipitation approach produced better outcomes for plant proteins isolated from oil-seed cakes than the acid precipitation method. © 2023 Society of Chemical Industry.
Furmonertinib (AST2818) 240mg QD. All patients enrolled into this group will receive furmonertinib 240mg daily.
This group include 20 patients with COPD and intermittent claudication. These patients can receive pursed lip breathing and aerobic exercise (by applying treadmill exercise for 20 min) with the usually pharmacological treatment, for 4 weeks (3 sessions per week).
Statin therapy (atorvastatin or rosuvastatin) will be administered with or without non-statin lipid modifying therapies (LMTs). Non-statin LMTs will be adjusted by physicians to achieve the LDL-C target level \<100 milligrams per deciliter (mg/dL).
This phase two, single-site study will utilize a double-blind, placebo-controlled, randomized, pre-/post-treatment design to investigate the effect of NAC dosing on brain GSH levels and measure temporally concordant plasma levels of several established circulating markers of oxidative stress. Three study groups, of 20 subjects each (for a total of 60 who completed all components of the study), will each be administered a different dose (0 mg/day, 900mg/day, 3600mg/day) of the study intervention over a four week period; N-acetylcysteine (NAC) treatment. Subjects receiving 0 mg/day dose will be administered a placebo. Baseline visit assessments will include blood collection, survey questionnaires, MRI and MRS imaging. Subjects whose initial screening confirms low GSH level at baseline will be provided with a 4-week supplement of anonymized NAC or placebo caplets. After 4 weeks, subjects will then undergo a follow-up visit to repeat the baseline assessments.
Patients treated with ONGENTYS can experience intense urges to gamble, increased sexual urges, intense urges to spend money, binge eating, and/or other intense urges, and the inability to control these urges while taking one or more dopaminergic therapies that increase central dopaminergic tone. In some cases, these urges were reported to have stopped when the dose was reduced, or the medication was discontinued. Because patients may not recognize these behaviors as abnormal, it is important for prescribers to specifically ask patients or their caregivers about the development of new or increased gambling urges, sexual urges, uncontrolled spending, or other urges while being treated with ONGENTYS. 

In Study 1 and Study 2, impulse control disorders occurred in 1% of patients treated with ONGENTYS 50 mg, and in no patient who received placebo. Re-evaluate the patient’s current therapy(ies) for Parkinson’s disease and consider stopping ONGENTYS if a patient develops such urges while taking ONGENTYS.

Use with caution in Parkinson’s patients with suspected or diagnosed dopamine dysregulation syndrome.
The episodic nature of migraine attacks presents a number of difficulties in characterizing disease severity. There are differences in the severity, frequency and intensity of attacks and the general effect of the disease in individuals. Information about any particular attack is not sufficient to characterize the overall severity of the disease. Accordingly, the Headache Impact Questionnaire (HIQ) was developed to evaluate the headache experience over a period of time instead of any headache. Developed to measure the impact and quality of life of individuals suffering from headache, hıq evaluates the frequency and duration of headache, the degree of pain severity, daily life activities, disruptions in work or school life, the influence of the individual's leisure activities and other symptoms that may occur. HIQ consists of 16 items and the higher the score shows the seriousness of the impact. The study is planned with 80 individuals with complaint of headache. After questioning the sociodemographic characteristics of the individuals, the patients will be asked to fill in HIQ, Migraine Disability Assessment Questionnaire, Headache Impact Test-6 and Short Form-36.Test-retest will be re-applied to those of the same individuals who can be reached after 1 week. The results will be analyzed using the SPSS version 22.0 computer package program.
Participants received deferasirox 20mg/kg/day OD for 12 months. Deferasirox was taken every morning 30 minutes before breakfast, if possible consistently around the same time between 7:00 and 9:00 AM. The tablets was dropped into water or orange juice and gently stirred for 1 to 3 minutes until completely dispersed.
PROBLEM TO BE SOLVED: To prepare a sheet of highly oil absorbing absorbent paper for makeup, having a high true absorbency for sebum by single use and further capable of providing characteristics of a high transparency after use thereof and provide a method for producing the paper. SOLUTION: This sheet of highly oil absorbing absorbent paper for makeup is prepared by mixing 100 pts.wt. Manila hemp (30 deg. SR beating degree) with 20 pts.wt. microtalc (having 1.7μm average particle diameter and 16.0 BET m<2> /g surface area), providing a homogeneous dispersion, fixing the resultant dispersion to fibers with a fixing agent and then forming the sheet of paper with a cylinder paper machine. A wire cloth having 0.2mm wire diameter and 16 mesh size is used as the wire cloth of the cylinder paper machine and an uneven layer is formed at 22g/m<2> basis weight with one vat. The resultant web is subsequently treated with a super calender to provide 1.0g/cm<3> density. Thereby, the sheet of highly oil absorbing absorbent paper for makeup is prepared.
The most common treatment for early stage lung cancers is to remove the cancer with surgery. Patients with serious underlying health problems like emphysema, diabetes, or heart disease who develop an early stage lung cancer may not be eligible for the standard surgical treatment. The most common alternative to surgery is conventional radiation treatment called fractionated radiotherapy. "Fractionated radiotherapy" means several weeks of treatment with daily radiation sessions. While this treatment is sometimes successful at killing the cancer, it is not as effective as surgery and may significantly damage the surrounding lung tissue.

Newer treatments using radiotherapy have been developed and used for patients with metastases (spreading cancer) to the lungs. Stereotactic radiotherapy uses a frame to guide highly focused beams of radiation at the cancer while avoiding the normal surrounding tissue. Stereotactic radiotherapy also uses a higher daily dose of radiation. The higher daily dose may be more effective than conventional radiotherapy at killing cancer cells and may also decrease side effects.
The invention discloses a valproic acid softgel and a preparation method thereof. The valproic acid softgel comprises a soft-capsule shell and a contained solution cladded by the soft-capsule gelatin shell. The contained solution is composed of the following compositions in percent by weight: 10-100% of valproic acid, 0-90% of divalproex sodium and 0-90% of a solubilizer. The preparation method for the valproic acid softgel comprises the following steps: A, preparing a gelatin solution; B, preparing a contained solution, specifically dissolving valproic acid or/and divalproex sodium in the solubilizer, and stirring uniformly for usage; and C, preparing the softgel, specifically respectively adding the container solution and the gelatin solution in a pelleting press, adjusting the loading capacity and the thickness of the capsule shell, pressing into pills, drying, wiping pills and packaing. The invention aims at providing the provided valproic acid softgel which is simple in composition, stable, effective, strong in adaptability and fast in effectiveness. The invention also aims at providing a divalproex sodium softgel which is simple in composition, stable, effective, strong in adaptability, fast in effectiveness and easy to prepare.
Sugar absorption inhibitors originating in evening primrose seeds which are highly efficacious in preventing and ameliorating diabetes and preventing obesity.  These sugar absorption inhibitors are characterized by containing as the active ingredient an alcoholic extract of evening primrose seeds. It is favorable that the above-described evening primrose seeds have been defatted. It is favorable that the above-described evening primrose seeds are extracted with ethanol, preferably ethanol containing 70 to 85% (v/v) of water. The above-described sugar absorption inhibitors are characterized by containing as the active ingredient polyphenol(s) originating in evening primrose seeds. It is favorable that the above-described polyphenol comprises one or more members selected from among gallic acid, ellagic acid, catechin, pentagalloyl glucose, procyanidin and proanthocyanidin. A process for producing the above-described sugar absorption inhibitors characterized by comprising the following steps A to C: A. the step of pressing evening primrose seeds to separate oily components therefrom, thus giving a press cake; B. the step of defatting the press cake with a fat-soluble organic solvent to give a defatted matter; and C. the step of extracting the defatted matter with an alcohol and concentrating or evaporating to dryness this extract.